Exchange: NASDAQ·Updated 03:08 PM EDT
News
all
press releases
Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’
Lilly’s second-quarter revenue jumped 48% and comfortably beat Wall Street estimates, driven primarily by strong demand for its blockbuster weight loss drugs Mounjaro and Zepbound.
Stocktwits
More News
NVO Stock Slumps After Late-Stage Trial Fails Primary Goal – Retail Says ‘Current Revenue Drivers’ Still Intact
Novo’s Phase 3 trial showed that investigational drug Ziltivekimab did not reduce major adverse cardiovascular events compared with the placebo
Stocktwits
Novo Nordisk Reportedly Escalates Legal Battle Against Eli Lilly – Even As Analysts See LLY Leading The GLP-1 Race
Novo Nordisk is seeking a preliminary U.S. court injunction to immediately block Lilly’s advertisements for Zepbound and Mounjaro, according to a Reuters report on Friday.
Stocktwits
Eli Lilly Moves Closer To Another Weight-Loss Drug: Retatrutide Clears Two More Phase 3 Trials Ahead Of FDA Filing
Retatrutide, a once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, met the primary endpoint in both the Triumph-2 and Triumph-3 Phase 3 studies.
Stocktwits
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
Zacks
HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst
Analysts and investors have turned their attention to a key regulatory meeting on peptides, a decision expected to trigger HIMS’ next phase of growth.
Stocktwits
HIMS Stock Set To Test A Crucial Resistance – Is Retail Expecting A Breakout?
In April, the stock faced resistance near $30 and saw selling pressure in the following weeks.  
Stocktwits
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Zacks
LLY Stock Heads To Record High – Here’s Why Retail’s Bullish On Latest GLP-1 Data
Eli Lilly reported promising data for Retatrutide and Foundayo at the American Diabetes Association (ADA) 86th Scientific Sessions over the weekend.
Stocktwits
TD Cowen Raises GLP-1 Sales Forecast To $150B By 2030 – Industry Leaders LLY, NVO To Remain Dominant
TD Cowen expects around 59 million patients worldwide to be using GLP-1 therapies by the end of the decade, up sharply from its previous estimate of 46 million.
Stocktwits

Advertisement|Remove ads.